3 recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 3 |
| Phase 2 | 2 | Recruiting 2 |
Follow Efficacy: new trials by email Literature Review of Efficacy trials Research Report on Efficacy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells - Spinal Cord Injury, Safety | Phase 1 | Recruiting | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 12 | 2025-07-02 | 2025-11-25 |
| Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors Test Product HY07121 - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 258 | 2024-10-24 | 2026-10-13 |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation Test product: HYP-2090PTSA - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 257 | 2024-02-04 | 2026-01-29 |
Central Nervous System Diseases (1) · Nervous System Diseases (1) · Spinal Cord Diseases (1) · Trauma, Nervous System (1) · Wounds and Injuries (1)
Sichuan Huiyu Pharmaceutical Co., Ltd (2) · XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. (1)
China (3)